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Abstract 25 
Background: Given the rapid increase in e-cigarette (EC) popularity and paucity of longitudinal health-26 
related data associated with this, there is an urgent need to assess the potential risks of long-term EC use. 27 
Objective: To compare exposure to nicotine, tobacco-related carcinogens and toxicants among cigarette-only 28 
smokers, and smokers and ex-smokers with long-term EC use or with use of nicotine replacement therapy 29 
(NRT; a product with known safety profile). 30 
Design: Cross-sectional study. 31 
Setting: United Kingdom. 32 
Participants: Five groups were purposively recruited: (1) cigarette-only users, (2) ex-smokers with long-term 33 
(≥6 months) EC-only or (3) NRT-only use, and (4) long-term dual cigarette-EC or (5) dual cigarette-NRT 34 
users (N=36-37 per group, total N=181). 35 
Measurements: Socio-demographic and smoking characteristics were assessed; participants provided urine 36 
and saliva samples, analysed for biomarkers of nicotine, tobacco-specific nitrosamines (TSNAs) and volatile 37 
organic compounds (VOCs). 38 
Results: After controlling for confounders, there were no clear group differences in salivary or urinary 39 
biomarkers of nicotine intake. EC-only and NRT-only users had significantly lower metabolite levels for 40 
TSNAs (including the carcinogenic metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol, NNAL) and 41 
for VOCs (including metabolites of the toxicants acrolein, acrylamide, acrylonitrile, 1,3-butadiene, ethylene 42 
oxide) compared with cigarette-only, dual cigarette-EC or cigarette-NRT users. EC-only users had 43 
significantly lower NNAL levels than all other groups. Cigarette-only, dual cigarette-NRT and cigarette-EC 44 
users had largely similar levels of TSNA and VOC metabolites. 45 
Limitations: Cross-sectional design with self-selected sample. 46 
Conclusions: Ex-smokers with long-term EC-only or NRT-only use may achieve approximately similar 47 
nicotine intake to cigarette-only smokers but results were variable. Long-term NRT-only and EC-only use, 48 
but not dual use with cigarettes, is associated with substantially reduced levels of measured carcinogens and 49 
toxicants relative to cigarette-only smoking. 50 
Primary source of funding: Cancer Research UK (C27061/A16929). 51 
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Introduction 54 
E-cigarettes (EC) are increasingly popular devices (1) that produce an aerosol by heating a solvent (e-55 
liquid) usually containing nicotine through a battery-powered heating element. Unlike smoked tobacco, 56 
nicotine can therefore be delivered to the respiratory tract without combustion (2). Despite this possible 57 
advantage, health concerns about EC remain regarding potential cytotoxicity, delivery of carcinogens (3), 58 
including carbonyls (4, 5), tobacco-specific N-nitrosamines (TSNAs, (6)) and heavy metals (4), effects on 59 
cardiovascular and respiratory function and inflammation (7) and nicotine delivery (8). Data on the effects of 60 
long-term EC use are needed to assess their risks and potential effectiveness accurately and to inform health 61 
professionals encountering EC users (9). 62 
 63 
To date, most studies have looked at toxicant concentrations in EC liquids or aerosol (e.g. (4, 6)) using 64 
cell-line or animal models (e.g. (7)). However, this may not provide accurate information as user 65 
characteristics, together with device characteristics and their interaction, determine actual body-level 66 
exposure, and thus potential health consequences (10). Three studies that have assessed body-level exposure 67 
found lower levels for carcinogens, including TSNAs, in recent ex-smokers using EC compared with a historic 68 
sample of smokers (11), and reductions in toxicants over a two- or four-week period in smokers switching to 69 
EC with or without concurrent smoking (12, 13). However, none of the studies involved long-term users, 70 
which is important given observed learning effects in EC use (14) (15), or included real-world control groups 71 
to reduce the risk of confounding when interpreting results of observational studies. 72 
 73 
Nicotine replacement therapy (NRT) users would be an appropriate control. Dual use with cigarettes 74 
of either EC or NRT is common, and there is some long-term use of both (16, 17). Both have been advocated 75 
as harm reduction products used to reduce risks associated with combustible tobacco use (18). However, 76 
unlike EC, the NRT safety profile is well established (e.g. (19)) and NRT effectiveness for smoking cessation 77 
through intial partial (20) or complete substitution (21) has been demonstrated. NRT is therefore 78 
recommended as a harm reduction strategy in several countries (22). 79 
 80 
5 
 
While longitudinal cohort studies and randomised controlled trials will provide the best data to answer 81 
questions concerning the safety and efficacy for smoking cessation of EC use, these designs are time- and 82 
resource-intensive. In the absence of long-term data, a more pragmatic approach is to compare smokers and 83 
ex-smokers as a function of EC use in real life settings. This study aimed to address the gap in the existing 84 
literature by measuring biomarker levels in long-term users of EC compared with an appropriate control, NRT 85 
users. Specifically, this study assessed whether long-term EC-only, NRT-only, dual cigarette-EC or dual 86 
cigarette-NRT use is associated with differences in metabolites of a) nicotine; b) TSNAs and c) volatile 87 
organic compounds (VOC) compared with cigarette-only smokers.  88 
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Methods 89 
Study design and procedure 90 
This cross-sectional study, carried out in January–June 2014 in London, UK sought to evaluate the 91 
range of toxicant levels measured in smokers and ex-smokers with or without concurrent long-term use of EC 92 
or NRT. The study methodology has been described elsewhere (23). Briefly, participants visited the laboratory 93 
for a single session, lasting 30 minutes, after abstaining from eating, drinking or using cigarettes or nicotine 94 
products an hour before their visit to standardise assessment. At the laboratory, after providing written consent, 95 
participants completed a short questionnaire assessing socio-demographic, smoking and product use 96 
characteristics and provided breath, saliva and urine samples. Expired air was assessed for carbon monoxide 97 
(CO) with a breathalyser (Micro IV Smokerlyzer, Bedfont Scientific, Kent, England). In addition, two saliva 98 
samples were collected with sterile dental rolls (Salivette®, Sarstedt Ltd, Leicester, England) which 99 
participants were asked to gently chew for about two minutes or until saturated. Urine was collected in a 100 
sealable, sterilised cup by participants on site and transferred by staff into cryovials. Urine and saliva samples 101 
were then kept frozen at -20°C until shipment in dry ice for analysis to laboratories at Roswell Park Cancer 102 
Institute (RPCI) and the U.S. Centers for Disease Control and Prevention (CDC). All participants were 103 
reimbursed for time and travel (£25). The study was approved by the University College London Ethics 104 
Committee (Project ID 0483/002). 105 
 106 
Participants 107 
Participants were purposively recruited in the greater London area using a variety of methods to 108 
increase sample diversity, including newspapers and online adverts, posters in pharmacies, and the use of 109 
marketing companies. Participants had to be ever smokers and were eligible to take part if they fulfilled the 110 
following inclusion criteria: current smokers had to smoke an average of five or more cigarettes per day for at 111 
least six months, and ex-smokers had to have stopped using tobacco products (including cigarettes, waterpipe, 112 
cigars, smokeless products such as snus or chewing tobacco) for at least six months. Because this study sought 113 
to evaluate the impact of long-term use of non-combustible nicotine delivery devices (NRT and EC), smokers 114 
(i.e. dual cigarette-EC or cigarette-NRT users) and ex-smokers (i.e. EC-only or NRT-only users) had to have 115 
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been using these products at least weekly for six or more months (users of nicotine-free products, e.g. using 116 
e-liquid without nicotine, were excluded). In practice, however, participants used products daily as indicated 117 
by latency to last product use across groups (Cigarettes-only: 1.4h; Dual cigarette-NRT: 4.3h; Dual cigarette-118 
EC: 1.3h; NRT-only: 24h; EC-only: 5.4h). Product use was verified by asking participants to bring in the NRT 119 
or EC that they were currently using, and smoking status was verified with CO readings (10 ppm cut-off (24)). 120 
Participants who used both NRT and EC were excluded as were those below 18 years of age, pregnant or with 121 
a history of heart or lung disease or bleeding gums, illness, or an active infection within 24 hours of their 122 
scheduled appointment.  123 
 124 
Measures 125 
Biomarkers of exposure 126 
Level of nicotine exposure was determined to assess effectiveness of nicotine-delivery products using 127 
two different methodologies. Saliva samples were analysed for nicotine, and its major metabolite cotinine, 128 
using established gas chromatography methodology (25, 26). Urine samples were analysed for main nicotine 129 
metabolites to derive total nicotine equivalents and for minor tobacco alkaloids using validated tandem mass 130 
spectrometry methodology (27, 28). 131 
Levels of urinary TSNA and VOC metabolites were determined using liquid chromatography 132 
atmospheric pressure ionization tandem mass spectrometry (29) and ultra-high performance liquid 133 
chromatography coupled with electrospray ionisation and tandem mass spectrometry (30), respectively, to 134 
assess the potential risk of nicotine-delivery products. While a comprehensive battery of metabolites was 135 
assessed (see Table S1), we focus here on well-established metabolites of compounds that are known to 136 
contribute significantly to smoking-related toxicological and carcinogenic risks (31-39) (see Table 1). All 137 
analyses of urinary and salivary biomarkers were carried out by the CDC and RPCI, respectively. 138 
 139 
Covariates 140 
Socio-demographic characteristics (age, sex, ethnicity, education, marital status) were assessed in 141 
addition to self-reported recently resolved physical illness (chest infection, cold/flu, sore throat, fever), 142 
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subjective well-being (happiness and satisfaction, both assessed with established single item measures (40)) 143 
and C-reactive protein (CRP) as a marker of inflammation (and thus potential health problems), measured in 144 
saliva and analysed with the ELISA method by Salimetrics Europe Ltd, UK (41). Smoking characteristics 145 
assessed included current and past daily cigarette consumption as a measure of dependence for smokers and 146 
ex-smokers, respectively, age at which participants had started smoking and the proportion of family or friends 147 
who smoke to gauge environmental tobacco smoke exposure. 148 
 149 
Analysis 150 
As this was a cross-sectional study, exposure biomarkers including metabolites of known tobacco-151 
related carcinogens and toxicants were used as proxies for future disease risk. Previous research on the 152 
association of the carcinogenic metabolite 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) with lung 153 
cancer suggests that medium-large reductions in NNAL levels (Cohen’s f=0.25-0.40) would result in an 154 
appreciable reduction in risk (42) and could thus be considered clinically meaningful in magnitude and warrant 155 
further investigation (43). A priori power calculation showed that 180 participants (36 per group) would 156 
provide 90% power to detect between-group differences of a medium effect size (Cohen’s f=0.3) in NNAL 157 
levels when comparing five groups, using analysis of variance (44). However, this calculation did not account 158 
for multiple outcomes being tested, and based on 35 biomarker outcomes reported here, power to detect such 159 
an effect size across all biomarkers would have been reduced to 54%. The sample size therefore only provided 160 
sufficient power (≥80%) to detect effects at the upper range of the estimate (Cohen’s f≥ 0.36) when accounting 161 
for multiple comparisons. 162 
 163 
Analyses were conducted with SPSS Version 22.0. In initial analysis of group differences on 164 
covariates, one-way ANOVAs were used for continuous and chi-square analysis for categorical covariates, 165 
respectively. Prior to the main analysis, urinary metabolites were standardised algebraically to account for 166 
individual differences in urine concentration by dividing metabolite data by the ratio of observed to age-, sex-167 
, and ethnicity-adjusted creatinine values and creatinine (measured by standard colorimetric method at RCPI) 168 
was also included as covariate in analysis (see Method 7 in 45). Due to non-normal distribution of data, 169 
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generalised linear models with a log link and gamma distribution were used to assess group differences in 170 
outcome measures, adjusted for all covariates and latency to product use. B coefficients were exponentiated 171 
to obtain percent change in biomarker levels in all groups compared with cigarette-only smokers. For pre-172 
specified tests of main effects of group, Type I errors were controlled using the false discovery rate (46) 173 
separately for socio-demographic comparisons (N=13) and biomarker comparisons (N=35). Where overall 174 
omnibus effects were considered significant, the Sidak correction was used in post-hoc analysis to determine 175 
between which (if any) groups differences persisted. Biomarker values below the limit of detection (LOD) 176 
were imputed using standard methodology (LOD divided by square root of 2 (47)), and biomarkers with 50% 177 
or more of values below the LOD were not analysed. 178 
 179 
Role of funding source 180 
This work was supported by Cancer Research UK (C27061/A16929) with additional funding from 181 
Cancer Research UK (C1417/A14135; C36048/A11654). JB’s post is funded by a fellowship from the Society 182 
for the Study of Addiction and CRUK also provide support (C1417/A7972; C44576/A19501). AM and RW 183 
are part of the UK Centre for Tobacco and Alcohol Studies, a UK Clinical Research Collaboration Public 184 
Health Research: Centre of Excellence. Funding from the Medical Research Council, British Heart 185 
Foundation, Cancer Research UK, Economic and Social Research Council and the National Institute for 186 
Health Research under the auspices of the UK Clinical Research Collaboration is gratefully acknowledged 187 
(MR/K023195/1). MLG was supported by the National Institute on Drug Abuse (NIDA) and the National 188 
Cancer Institute (NCI) of the National Institutes of Health under Award Number R01DA037446 and P30 189 
CA016056, respectively, and by an award from Roswell Park Alliance Foundation. The content is solely the 190 
responsibility of the authors and does not necessarily represent the official views of the National Institutes of 191 
Health and the US Food and Drug Administration. The funders of the study had no role in study design, data 192 
collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access 193 
to all the data in the study and had final responsibility for the decision to submit for publication.  194 
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Results 195 
Overall, participants were relatively young, mainly male, white, had at least a high school education, 196 
and about half were single (see Table 2). On average, participants had started smoking in their late teens, 197 
smoking nearly one pack a day, with a substantial proportion (16%-51%) of their family or friends smoking. 198 
Salivary CRP levels were within the range observed for healthy adults (0.05-64.3 μg/L) (48) and reported 199 
well-being levels comparable to that of representative population samples (40). There were some group 200 
differences: the proportion of females varied from 19.4% in EC-only users to 61.1% in dual cigarette-NRT 201 
users, fewer EC-only users were female; NRT-only users had started smoking the latest and EC-only users 202 
had the lowest proportion of family or friends who smoke. There was also considerable variation between 203 
groups in terms of ethnicity, marital status, cigarette consumption, recent illness and reported happiness levels 204 
(Table 2). 205 
 206 
As previously reported, length of product use was broadly similar across group at around 17 months, 207 
and mean daily NRT and EC use, measured by self-reported nicotine dose, was higher for NRT-only and EC-208 
only users than for dual cigarette-NRT and cigarette-EC users (see (23) for details). In terms of the product 209 
type used, first generation ‘cig-a-likes’ with replaceable or disposable cartridges were most popular among 210 
dual cigarette-EC users (60.0%) and third/fourth generation advanced personal vaporisers most popular among 211 
EC-only users (47.2 %), with refillable pen-style, second generation EC equally popular among dual cigarette-212 
EC (31.4%) and EC-only (36.1%) users. For both dual cigarette-NRT and NRT-only users, gum (44.4% and 213 
33.3%, respectively) and patches (both 33.3%) were the most popular products, and a similar proportion 214 
(27.8%) used more than one NRT product. 215 
 216 
a) Nicotine levels 217 
Nicotine intake from different products was roughly comparable (Figure 1), although there was some 218 
variation across groups (Table S1). In terms of urinary biomarkers, users of all products had levels of total 219 
nicotine equivalents at least as high as cigarette-only smokers in adjusted analysis (see Table 3). Findings in 220 
relation to salivary biomarkers varied. Dual cigarette-NRT users had relatively low nicotine and cotinine levels 221 
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and EC-only users had relatively low nicotine levels, at around half that of cigarette-only users, with other 222 
groups obtaining levels slightly below or above those from cigarette-only users (Table 3). The minor tobacco 223 
alkaloids anabasine and anatabine which are specific to tobacco as opposed to nicotine exposure, clearly 224 
distinguished between smokers and ex-smokers, with significantly lower levels compared with cigarette-only, 225 
dual cigarette-NRT or cigarette-EC users (Table S1). 226 
 227 
b) TSNA levels 228 
There were clear differences in levels of the carcinogen metabolite NNAL (Figure 2). NRT-only and 229 
EC-only users had markedly lower levels than cigarette-only, dual cigarette-NRT and cigarette-EC users 230 
(p<0.001), with EC-only users having significantly lower levels than all other groups, at less than 3% of 231 
cigarette-only smoker levels (Table 3). Compared with cigarette-only smokers, there were no large differences 232 
in NNAL levels for dual cigarette-EC users but dual cigarette-NRT users had somewhat lower levels. Results 233 
followed a similar, albeit less pronounced, pattern for the other TSNAs measured (Table S1). 234 
 235 
c) VOC levels 236 
EC-only users had the lowest overall levels of the major urinary VOC metabolites, with acrylonitrile 237 
levels as low as 2.9% of cigarette-only smokers, and NRT-only users had the second lowest overall, with 238 
acrylonitrile levels as low as 10.5% of cigarette-only smokers (Table 3). By contrast, dual cigarette-NRT, 239 
cigarette-EC and cigarette-only users all had very similar VOC metabolite levels (Figure 2). Compared with 240 
all other groups, NRT-only and EC-only users at least halved the reference values of cigarette-only smokers 241 
(see Table 3), and had significantly lower levels of all major metabolites of selected toxicant and carcinogen 242 
VOCs (all p<0.001, Table S1). 243 
 244 
Results were largely confirmed when looking at other VOC metabolites that were assessed, with EC-245 
only users generally displaying the lowest levels, followed by NRT-only users and no detectable differences 246 
between dual cigarette-NRT, cigarette-EC and cigarette-only users (see Table S1). The only exceptions were 247 
metabolites of benzene (N-Acetyl-S-(phenyl)-L-cysteine (PMA) and muconic acid (MU)), carbon disulphide 248 
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(2-thioxothiazolidine-4-carboxylic acid (TTCA)) and styrene (N-Acetyl-S-(1 and 2-phenyl-2-hydroxyethyl)-249 
L-cysteine (PHEMA) and phenylglyoxylic acid (PGA)). Dual cigarette-EC users had somewhat higher PMA, 250 
MU and PHEMA levels and dual cigarette-NRT and dual cigarette-EC users had somewhat higher PGA levels 251 
than other groups (Table S1). There were no appreciable group differences in TTCA levels. However, these 252 
metabolites were either non-specific to the parent VOC measured (MU, TTCA have dietary contributions, 253 
PGA is a metabolite of ethylbenzene and styrene exposure) or had low detection rates (PMA and PHEMA; 254 
see Table S2).  255 
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Discussion 256 
This is, to our knowledge, the first direct comparison of nicotine, important carcinogen and toxicant 257 
metabolite levels in long-term users of EC or NRT. We find that ex- smokers who had switched to exclusive 258 
EC or NRT use obtained roughly similar levels of nicotine compared with cigarette-only smokers, but results 259 
were variable. Exclusive use of NRT, and in particular of EC, but not dual use with cigarettes, was associated 260 
with lower levels of known tobacco-related carcinogens and toxicants measured in this study compared with 261 
cigarette-only use. 262 
 263 
The finding that NRT-only or EC-only use is associated with roughly similar nicotine intake to 264 
cigarette-only use supports the view that users seek a particular level of nicotine intake, irrespective of the 265 
delivery system (49), and adjust product use accordingly (50). The finding is consistent with more recent (51) 266 
but not older (8) studies on nicotine delivery from EC and may reflect the improved design of newer 267 
generations of EC products (52), highlighting the importance of focusing on experienced, long-term rather 268 
than naïve, short-term users. Similarly, efficient nicotine intake from exclusive NRT use has been observed 269 
in long-term (53) but not short and intermediate-term NRT users (54). The fact that intake was largely similar 270 
for both groups also suggests that better craving reductions observed in users of EC compared with NRT (23, 271 
55) may be due to factors other than nicotine delivery, such as the greater behavioural similarity of EC use (as 272 
opposed to NRT use) with smoking. This is consistent with research on non-nicotine sensory factors that have 273 
been shown to influence tobacco withdrawal (56). However, it should be noted that this study was not powered 274 
to detect anything other than relatively large effects, so results are indeterminate regarding smaller differences 275 
in nicotine intake between these groups. 276 
 277 
The lower carcinogen and toxicant levels associated with NRT-only and EC-only use in this study 278 
confirm the known low risk for long-term NRT product use (57). They also underscore the translation of 279 
greatly reduced concentrations of some carcinogens and toxicants from e-liquids and aerosol (4, 6, 58) to 280 
body-level exposure, contrary to worries that long-term EC use would result in substantial harmful exposure 281 
(59). Given the involvement of these TSNAs and VOCs with cancer, cardiovascular and pulmonary diseases 282 
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(e.g. 42, 60), these results suggest that complete substitution may result in reducing disease risk and supports 283 
the assertion that EC use may to be less harmful than smoking (2, 61-63). In this study, there was no evidence 284 
that long-term EC-only use is associated with greater carcinogen or toxicant levels than NRT-only use; if 285 
anything, on some measures it was associated with lower levels. While this could be due to occasional cigarette 286 
smoking lapses by long-term NRT-only users, this is unlikely to have made a substantial contribution given 287 
very low levels of tobacco-specific (as opposed to nicotine-specific) biomarkers for acrylonitrile, anabasine 288 
and anatabine (64, 65) in this group. Alternatively, these differences may reflect typical low-level 289 
contamination in these products (e.g. with nitrosamines from tobacco-derived nicotine (66)), non-specificity 290 
of the metabolite for the toxicant (e.g. muconic acid for benzene (67)), or non-smoking related environmental 291 
sources of toxicant exposure (e.g. for styrene (68)). Contrary to findings from a recent short-term switching 292 
study (12), dual cigarette-NRT or cigarette-EC use was not associated with appreciable reductions in 293 
carcinogen and toxicant levels. This may be because participants in the current study may have been even 294 
heavier smokers prior to starting concurrent EC or NRT use, thus masking the benefit of potential partial 295 
substitution in our cross-sectional study, or because dual users used non-combustible products to bridge times 296 
of non-smoking and thus did not actually reduce their cigarettes consumption. Alternatively, it may reflect 297 
either differences in study design, e.g. different usage pattern in long-term as opposed to short-term users, or 298 
the relatively low power to detect smaller, yet meaningful, effects in this study. Further longitudinal research 299 
is needed to differentiate between these explanations. 300 
 301 
The findings have several implications. While complete long-term switching to EC may produce a net 302 
benefit for the health outcomes of the smoking population, given the association with very low levels of 303 
dangerous constituents measured in this study similar in magnitude to NRT, it is only likely to be beneficial 304 
if complete cessation of cigarettes is achieved. Thus, dual users should be encouraged to cease using 305 
combustible products to reduce long-term health risks. Our results also indicate that machine-derived and 306 
actual body-level exposure to toxicants can be very different as shown, for instance, by greatly reduced 307 
aldehyde levels in EC users here compared with reportedly high levels in EC aerosol under certain laboratory 308 
conditions ((5) but see (69)). Lastly, it should be noted that while exclusive EC and NRT use was associated 309 
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with marked reductions in carcinogen and toxicant levels compared with cigarette-only smokers, it did not 310 
eliminate exposure (and thus possible health risks) completely. Full cessation of all nicotine products remains 311 
the best option to avoid harm. 312 
 313 
The study had several limitations. Even though participants were recruited using diverse methods, 314 
resulting in a sample broadly similar to the population of NRT/EC users (16, 70), and we controlled for 315 
important confounders, group differences may not generalise and reflect self-selection. The sample was too 316 
small to allow more sophisticated analyses to evaluate the association of different types of EC or NRT (and 317 
other characteristics such as EC flavourings) with intake, and we may not have picked up small but important 318 
differences in exposure levels. In particular, the lack of group differences in nicotine intake has to be 319 
interpreted cautiously given the low power to detect smaller effects and the variability across different urinary 320 
and salivary measures. Lastly, we did not assess indirect exposure and the analysis was limited by the number 321 
of biomarkers available and spot sampling, which can only provide a snapshot of exposure. However, given 322 
the lack of long-term data, we chose this pragmatic design to evaluate quickly potentially important 323 
associations of EC use with carcinogen and toxicant intake to inform further longitudinal work. Moreover, the 324 
relatively slow pharmacokinetics of the assessed metabolites (71) provides stable estimates of recent exposure 325 
and should militate against variations associated with different usage patterns of different products. Future 326 
work should attempt to sample a larger range of biomarkers over a longer period of time, including biomarkers 327 
of actual harm such as lung function measures, and evaluate the impact of potential interactions of user with 328 
device characteristics on delivery of toxicants to users and bystanders. 329 
 330 
In conclusion, exclusive long-term NRT or EC use among ex-smokers is associated with substantially 331 
reduced levels of select carcinogens and toxicants compared with cigarette smoking; however, concurrent use 332 
with cigarettes appears not to be. We found no evidence that EC-only compared with NRT-only use is 333 
associated with greater carcinogen and toxicant levels measured in this study. Nicotine delivery, though 334 
variable, is roughly comparably to cigarettes, but smaller meaningful differences may exist.  335 
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Figure legends 550 
Figure 1: ^ Boxplots show median with interquartile range, IQR (25%-75%); error bars show Tukey’s whiskers 551 
and cross indicates arithmetic mean (geometric means are provided in Table S1); Solid grey circles show 552 
outliers; *Measured in urine: data are raw values divided by ratio of observed to covariate-adjusted creatinine 553 
levels; values below the limit of detection (LOD) were imputed by LOD divided by square root of 2; 554 
†Measured in saliva; There were no significant differences between groups; NRT – Nicotine replacement 555 
therapy; EC – Electronic cigarette; Cig-Cigarette 556 
Figure 2: ^Data are raw values divided by ratio of observed to covariate-adjusted creatinine levels; values 557 
below the limit of detection (LOD) were imputed by LOD divided by square root of 2; *Boxplots show median 558 
with interquartile range (25%-75%); error bars show Tukey’s whiskers and cross indicates arithmetic mean 559 
(geometric means are provided in Table S1); Solid grey circles show outliers; Significant pairwise 560 
comparisons are presented in Table S1; NRT – Nicotine replacement therapy; EC – Electronic cigarette; Cig-561 
Cigarette 562 
